ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

XNCR Xencor Inc

20.58
-0.73 (-3.43%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Xencor Inc NASDAQ:XNCR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.73 -3.43% 20.58 20.60 21.14 21.11 20.39 21.04 511,742 01:00:00

Xencor to Present at Upcoming Investor Conferences

28/02/2024 9:01pm

Business Wire


Xencor (NASDAQ:XNCR)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Xencor Charts.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference Date: Wednesday, March 6, 2024 Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT Location: Boston
  • Leerink Partners Global Biopharma Conference Date: Tuesday, March 12, 2024 Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT Location: Miami
  • Jefferies Biotech on the Bay Summit Date: Wednesday, March 13, 2024 Location: Miami
  • Barclays Global Healthcare Conference Date: Thursday, March 14, 2024 Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT Location: Miami

Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Charles Liles cliles@xencor.com (626) 737-8118

1 Year Xencor Chart

1 Year Xencor Chart

1 Month Xencor Chart

1 Month Xencor Chart